Tang et al., the STAT3 ASO activity was checked in phase II clinical trial conducted evaluating combination treatment with danvatirsen (ASO that inhibits STAT3) and durvalumab (anti-PD-L1) in patients NSCLC [42]. This evidence concerns the gene STAT3 and non-small cell lung carcinoma.